The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium
will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS),
hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for
this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the
discovery and development of biomarkers.